Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival
Nowadays, advanced irradiation techniques make it possible to escalate safely the dose in prostate cancer. We studied the effect of a higher dose on tumor control in a randomized trial with a median follow-up of 110months.
Autor*in: |
Heemsbergen, Wilma D. [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2014 |
---|
Schlagwörter: |
---|
Umfang: |
6 |
---|
Übergeordnetes Werk: |
Enthalten in: Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells - Han, Xiaobing ELSEVIER, 2021, journal of the European Society for Therapeutic Radiology and Oncology, Amsterdam [u.a.] |
---|---|
Übergeordnetes Werk: |
volume:110 ; year:2014 ; number:1 ; pages:104-109 ; extent:6 |
Links: |
---|
DOI / URN: |
10.1016/j.radonc.2013.09.026 |
---|
Katalog-ID: |
ELV039202208 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV039202208 | ||
003 | DE-627 | ||
005 | 20230624055304.0 | ||
007 | cr uuu---uuuuu | ||
008 | 180603s2014 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.radonc.2013.09.026 |2 doi | |
028 | 5 | 2 | |a GBVA2014004000012.pica |
035 | |a (DE-627)ELV039202208 | ||
035 | |a (ELSEVIER)S0167-8140(13)00518-5 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 610 | |
082 | 0 | 4 | |a 610 |q DE-600 |
082 | 0 | 4 | |a 570 |a 540 |q VZ |
100 | 1 | |a Heemsbergen, Wilma D. |e verfasserin |4 aut | |
245 | 1 | 0 | |a Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival |
264 | 1 | |c 2014 | |
300 | |a 6 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a Nowadays, advanced irradiation techniques make it possible to escalate safely the dose in prostate cancer. We studied the effect of a higher dose on tumor control in a randomized trial with a median follow-up of 110months. | ||
650 | 7 | |a Clinical trial |2 Elsevier | |
650 | 7 | |a Dose-escalation |2 Elsevier | |
650 | 7 | |a Prostate cancer |2 Elsevier | |
700 | 1 | |a Al-Mamgani, Abrahim |4 oth | |
700 | 1 | |a Slot, Annerie |4 oth | |
700 | 1 | |a Dielwart, Michel F.H. |4 oth | |
700 | 1 | |a Lebesque, Joos V. |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Han, Xiaobing ELSEVIER |t Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |d 2021 |d journal of the European Society for Therapeutic Radiology and Oncology |g Amsterdam [u.a.] |w (DE-627)ELV00004122X |
773 | 1 | 8 | |g volume:110 |g year:2014 |g number:1 |g pages:104-109 |g extent:6 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.radonc.2013.09.026 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 110 |j 2014 |e 1 |h 104-109 |g 6 | ||
953 | |2 045F |a 610 |
author_variant |
w d h wd wdh |
---|---|
matchkey_str |
heemsbergenwilmadalmamganiabrahimslotann:2014----:ogemeutoteucrnoiepottcnetilmatfoesaainnoabohm |
hierarchy_sort_str |
2014 |
publishDate |
2014 |
allfields |
10.1016/j.radonc.2013.09.026 doi GBVA2014004000012.pica (DE-627)ELV039202208 (ELSEVIER)S0167-8140(13)00518-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Heemsbergen, Wilma D. verfasserin aut Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nowadays, advanced irradiation techniques make it possible to escalate safely the dose in prostate cancer. We studied the effect of a higher dose on tumor control in a randomized trial with a median follow-up of 110months. Clinical trial Elsevier Dose-escalation Elsevier Prostate cancer Elsevier Al-Mamgani, Abrahim oth Slot, Annerie oth Dielwart, Michel F.H. oth Lebesque, Joos V. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:110 year:2014 number:1 pages:104-109 extent:6 https://doi.org/10.1016/j.radonc.2013.09.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 110 2014 1 104-109 6 045F 610 |
spelling |
10.1016/j.radonc.2013.09.026 doi GBVA2014004000012.pica (DE-627)ELV039202208 (ELSEVIER)S0167-8140(13)00518-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Heemsbergen, Wilma D. verfasserin aut Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nowadays, advanced irradiation techniques make it possible to escalate safely the dose in prostate cancer. We studied the effect of a higher dose on tumor control in a randomized trial with a median follow-up of 110months. Clinical trial Elsevier Dose-escalation Elsevier Prostate cancer Elsevier Al-Mamgani, Abrahim oth Slot, Annerie oth Dielwart, Michel F.H. oth Lebesque, Joos V. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:110 year:2014 number:1 pages:104-109 extent:6 https://doi.org/10.1016/j.radonc.2013.09.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 110 2014 1 104-109 6 045F 610 |
allfields_unstemmed |
10.1016/j.radonc.2013.09.026 doi GBVA2014004000012.pica (DE-627)ELV039202208 (ELSEVIER)S0167-8140(13)00518-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Heemsbergen, Wilma D. verfasserin aut Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nowadays, advanced irradiation techniques make it possible to escalate safely the dose in prostate cancer. We studied the effect of a higher dose on tumor control in a randomized trial with a median follow-up of 110months. Clinical trial Elsevier Dose-escalation Elsevier Prostate cancer Elsevier Al-Mamgani, Abrahim oth Slot, Annerie oth Dielwart, Michel F.H. oth Lebesque, Joos V. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:110 year:2014 number:1 pages:104-109 extent:6 https://doi.org/10.1016/j.radonc.2013.09.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 110 2014 1 104-109 6 045F 610 |
allfieldsGer |
10.1016/j.radonc.2013.09.026 doi GBVA2014004000012.pica (DE-627)ELV039202208 (ELSEVIER)S0167-8140(13)00518-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Heemsbergen, Wilma D. verfasserin aut Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nowadays, advanced irradiation techniques make it possible to escalate safely the dose in prostate cancer. We studied the effect of a higher dose on tumor control in a randomized trial with a median follow-up of 110months. Clinical trial Elsevier Dose-escalation Elsevier Prostate cancer Elsevier Al-Mamgani, Abrahim oth Slot, Annerie oth Dielwart, Michel F.H. oth Lebesque, Joos V. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:110 year:2014 number:1 pages:104-109 extent:6 https://doi.org/10.1016/j.radonc.2013.09.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 110 2014 1 104-109 6 045F 610 |
allfieldsSound |
10.1016/j.radonc.2013.09.026 doi GBVA2014004000012.pica (DE-627)ELV039202208 (ELSEVIER)S0167-8140(13)00518-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Heemsbergen, Wilma D. verfasserin aut Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Nowadays, advanced irradiation techniques make it possible to escalate safely the dose in prostate cancer. We studied the effect of a higher dose on tumor control in a randomized trial with a median follow-up of 110months. Clinical trial Elsevier Dose-escalation Elsevier Prostate cancer Elsevier Al-Mamgani, Abrahim oth Slot, Annerie oth Dielwart, Michel F.H. oth Lebesque, Joos V. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:110 year:2014 number:1 pages:104-109 extent:6 https://doi.org/10.1016/j.radonc.2013.09.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 110 2014 1 104-109 6 045F 610 |
language |
English |
source |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:110 year:2014 number:1 pages:104-109 extent:6 |
sourceStr |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:110 year:2014 number:1 pages:104-109 extent:6 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Clinical trial Dose-escalation Prostate cancer |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
authorswithroles_txt_mv |
Heemsbergen, Wilma D. @@aut@@ Al-Mamgani, Abrahim @@oth@@ Slot, Annerie @@oth@@ Dielwart, Michel F.H. @@oth@@ Lebesque, Joos V. @@oth@@ |
publishDateDaySort_date |
2014-01-01T00:00:00Z |
hierarchy_top_id |
ELV00004122X |
dewey-sort |
3610 |
id |
ELV039202208 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV039202208</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624055304.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2013.09.026</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014004000012.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV039202208</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(13)00518-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Heemsbergen, Wilma D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nowadays, advanced irradiation techniques make it possible to escalate safely the dose in prostate cancer. We studied the effect of a higher dose on tumor control in a randomized trial with a median follow-up of 110months.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dose-escalation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Al-Mamgani, Abrahim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Slot, Annerie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dielwart, Michel F.H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lebesque, Joos V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:110</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:104-109</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2013.09.026</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">110</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">104-109</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
author |
Heemsbergen, Wilma D. |
spellingShingle |
Heemsbergen, Wilma D. ddc 610 ddc 570 Elsevier Clinical trial Elsevier Dose-escalation Elsevier Prostate cancer Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival |
authorStr |
Heemsbergen, Wilma D. |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00004122X |
format |
electronic Article |
dewey-ones |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry & allied sciences |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
610 610 DE-600 570 540 VZ Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival Clinical trial Elsevier Dose-escalation Elsevier Prostate cancer Elsevier |
topic |
ddc 610 ddc 570 Elsevier Clinical trial Elsevier Dose-escalation Elsevier Prostate cancer |
topic_unstemmed |
ddc 610 ddc 570 Elsevier Clinical trial Elsevier Dose-escalation Elsevier Prostate cancer |
topic_browse |
ddc 610 ddc 570 Elsevier Clinical trial Elsevier Dose-escalation Elsevier Prostate cancer |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
a a m aam a s as m f d mf mfd j v l jv jvl |
hierarchy_parent_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
hierarchy_parent_id |
ELV00004122X |
dewey-tens |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry |
hierarchy_top_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV00004122X |
title |
Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival |
ctrlnum |
(DE-627)ELV039202208 (ELSEVIER)S0167-8140(13)00518-5 |
title_full |
Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival |
author_sort |
Heemsbergen, Wilma D. |
journal |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
journalStr |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology 500 - Science |
recordtype |
marc |
publishDateSort |
2014 |
contenttype_str_mv |
zzz |
container_start_page |
104 |
author_browse |
Heemsbergen, Wilma D. |
container_volume |
110 |
physical |
6 |
class |
610 610 DE-600 570 540 VZ |
format_se |
Elektronische Aufsätze |
author-letter |
Heemsbergen, Wilma D. |
doi_str_mv |
10.1016/j.radonc.2013.09.026 |
dewey-full |
610 570 540 |
title_sort |
long-term results of the dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival |
title_auth |
Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival |
abstract |
Nowadays, advanced irradiation techniques make it possible to escalate safely the dose in prostate cancer. We studied the effect of a higher dose on tumor control in a randomized trial with a median follow-up of 110months. |
abstractGer |
Nowadays, advanced irradiation techniques make it possible to escalate safely the dose in prostate cancer. We studied the effect of a higher dose on tumor control in a randomized trial with a median follow-up of 110months. |
abstract_unstemmed |
Nowadays, advanced irradiation techniques make it possible to escalate safely the dose in prostate cancer. We studied the effect of a higher dose on tumor control in a randomized trial with a median follow-up of 110months. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
container_issue |
1 |
title_short |
Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival |
url |
https://doi.org/10.1016/j.radonc.2013.09.026 |
remote_bool |
true |
author2 |
Al-Mamgani, Abrahim Slot, Annerie Dielwart, Michel F.H. Lebesque, Joos V. |
author2Str |
Al-Mamgani, Abrahim Slot, Annerie Dielwart, Michel F.H. Lebesque, Joos V. |
ppnlink |
ELV00004122X |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth |
doi_str |
10.1016/j.radonc.2013.09.026 |
up_date |
2024-07-06T20:02:07.695Z |
_version_ |
1803861232394960896 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV039202208</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624055304.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2013.09.026</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014004000012.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV039202208</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(13)00518-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Heemsbergen, Wilma D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nowadays, advanced irradiation techniques make it possible to escalate safely the dose in prostate cancer. We studied the effect of a higher dose on tumor control in a randomized trial with a median follow-up of 110months.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dose-escalation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Al-Mamgani, Abrahim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Slot, Annerie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dielwart, Michel F.H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lebesque, Joos V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:110</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:104-109</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2013.09.026</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">110</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">104-109</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
score |
7.399208 |